This concept is particularly strengthened by the fact that DUSP1 upregulation following traditional chemotherapies is associated with worse tumor burden and drug resistance in several malignancies and thus, DUSP1 inhibition would be expected to improve clinical outcomes. This evidence concerns the gene DUSP1 and neoplasm.